Zobrazeno 1 - 10
of 693
pro vyhledávání: '"Rubin LJ"'
Publikováno v:
Drug Design, Development and Therapy, Vol 2012, Iss default, Pp 19-28 (2012)
Richard N Channick1, Robert Voswinckel2,3, Lewis J Rubin41Pulmonary Hypertension Program, Massachusetts General Hospital, Boston, MA, USA; 2University of Giessen Lung Center, Dept. of Internal Medicine, Giessen; 3Max-Planck-Institute for Heart and Lu
Externí odkaz:
https://doaj.org/article/bba6d819a1354526862006f2f8693e37
Autor:
Galiè, N, Rubin, LJ, Hoeper, MM, Jansa, P, Al-Hiti, H, Meyer, GMB, Chiossi, E, Kusic-Pajic, A, Simonneau, G
Publikováno v:
In The Lancet 2008 371(9630):2093-2100
Autor:
Distler, O, Behrens, F, Pittrow, D, Huscher, D, Denton, Cp, Foeldvari, I, Humbert, M, Matucci Cerinic, M, Nash, P, Opitz, Cf, Rubin, Lj, Seibold, Jr, Furst, De, EPOSS Omeract Group including Ahmadi Simab, K, Albera, Carlo, Bolster, Mb, Brühlmann, P, Burger, C, Chan, K, Chatterjee, S, Clements, P, Confalonieri, M, Csuka, Me, Farber, H, Fessler, B, Foley, R, Frantz, R, Gran, Jt, Highland, K, Hoeper, M, Hsu, V, Inanc, M, Jansa, P, Johnson, S, Kahaleh, B, Kawut, Sm, Keogh, A, Khanna, D, Kähler, Cm, Lang, I, Mahmud, Th, Mandel, J, Mathier, M, Mayes, M, Mchugh, N, Mckown, K, Mclaughlin, V, Medsger TA Jr, Mehta, S, Merkel, Pa, Mubarak, K, Nathan, S, Oudiz, R, Palevsky, H, Park, M, Pope, J, Presberg, K, Ralph, D, Rich, S, Rothfield, N, Rubenfire, M, Scorza, R, Senecal, Jl, Shanahan, J, Silver, R, Staehler, G, Steen, V, Strange, C, Sweiss, N, Taichman, D, Talwar, A, Voskuyl, A, Wigley, F, Williamson, T, Wollheim, F.
Publikováno v:
Arthritis & Rheumatism. 59:867-875
Objective. Outcome measures for pulmonary arterial hypertension associated with systemic sclerosis (PAH-SSc) are only partially validated. The aim of the present study was to establish an expert consensus regarding which outcome measures are most app
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30048b8708e76edc075ba25b5ba8df76
https://doi.org/10.1002/art.23718
https://doi.org/10.1002/art.23718
Autor:
Ghofrani, Ha, Galiè, N, Grimminger, F, Grünig, E, Humbert, M, Jing, Zc, Keogh, Am, Langleben, D, Kilama, Mo, Fritsch, A, Neuser, D, Rubin, Lj, 1 Study Group including Bortman G, Patent, Keogh, A, Kermeen, F, Feenstra, J, Williams, T, Reeves, G, Kilpatrick, D, Lang, I, Kahler, C, Mascherbauer Steringer, R, Vachiery, Jl, Delcroix, M, Meyer, G, Arakaki, J, Santana, M, Waetge, D, Granton, J, Helmersen, D, He, J, Jing, Z, Zhou, D, Huang, Y, Wang, C, Jansa, P, Neilsen Kudsk JE, Hachulla, E, De Groote, P, Frachon, I, Bourdin, A, Pison, C, Bauer, F, Dromer, C, Marquette, Ch, Degano, B, Neurohr, C, Wilkens, H, Hoffken, G, Hoeper, M, Ghofrani, A, Wirtz, H, Rosenkranz, S, Ewert, R, Orfanos, S, Kramer, M, Ben Gal, T, Scelsi, L, Vizza, C, Harari, S, Confalonieri, M, Albera, Carlo, Fukumoto, Y, Sano, M, Hatano, M, Saji, T, Tanaka, S, Takeda, Y, Takehara, K, Matsubara, H, Kihara, Y, Shiohira, Y, Kawai, H, Homma, S, Satoh, T, Tokunaga, T, Ishizaki, T, Diaz, C, Zamudio, T, De Los Rios, M, Estupian, S, Cacho, Jr, Gamba, M, Beckert, L, Torbicki, A, Castro, G, Reis, A, Agapito, A, Martins, S, Kim, H, Lee, S, Chang, H, Song, Y, Chazova, I, Moiseeva, O, Lim, S, Yip, J, Barbera, J, Roman, A, Palma Jdel, C, Reitan, O, Soderberg, S, Jansson, K, Speich, R, Hsu, Hh, Lin, Hy, Cheng, Cc, Phrommintikul, A, Jaimchariyatam, N, Sayin, T, Kultursay, H, Ongen, G, Pepke Zaba, J, Coghlan, G, Peacock, A, Gibbs, J, Wagoner, L, Badesch, D, Frost, A, Hill, N, Allen, R, Waxman, A, Sood, N, Torres, F, Minai, O, Shapiro, S, Klinger, J, Engel, P, Garcia, H, Schuller, D, Poch, D, Rosenzweig, E, Mcconnell, J, Rischard, F, Olschewski, H, Haverkamp, W, Lehmacher, W, Hoischen, S, Collamati, S, Dehay, J, Hallmann, M, Menezes, F.
Riociguat, a soluble guanylate cyclase stimulator, has been shown in a phase 2 trial to be beneficial in the treatment of pulmonary arterial hypertension. METHODS: In this phase 3, double-blind study, we randomly assigned 443 patients with symptomati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08a8fd42189d6ac9c1d50e70aff46618
http://hdl.handle.net/2318/152936
http://hdl.handle.net/2318/152936
Autor:
Rubin LJ, Badesch DB, Fleming TR, Simonneau G, Ghofrani HA, Oakes M, Layton G, Serdarevic Pehar M, McLaughlin VV, Barst RJ, behalf of the SUPER 2 Study Group, GALIE', NAZZARENO
Publikováno v:
Chest. 140(5)
Background: The long-term safety and tolerability of sildenafil treatment of pulmonary arterial hypertension (PAH) were assessed. Methods: Two hundred fifty-nine of 277 randomized and treated patients completed a 12-week, double-blind, placebo-contro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::e50cd59d03bf8a281c998e00e55915f9
https://pubmed.ncbi.nlm.nih.gov/21546436
https://pubmed.ncbi.nlm.nih.gov/21546436
Autor:
Oudiz RJ, Olschewski H, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Harrison BC, Despain D, Dufton C, Rubin LJ, ARIES Study Group, GALIE', NAZZARENO
Objectives This study evaluated the safety and efficacy of ambrisentan for a period of 2 years in patients with pulmonary arterial hypertension (PAH). Background Ambrisentan is an oral, once-daily endothelin receptor antagonist that is selective for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cf92f363b069fa0c2b1f9645a3573d0
http://hdl.handle.net/11585/88811
http://hdl.handle.net/11585/88811
Autor:
Simonneau G, Rubin LJ, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB, GALIE', NAZZARENO
Oral sildenafil and intravenous epoprostenol have independently been shown to be effective in patients with pulmonary arterial hypertension. OBJECTIVE: To investigate the effect of adding oral sildenafil to long-term intravenous epoprostenol in patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4094::efca4359200f69c7429392969811e25e
http://hdl.handle.net/11585/76286
http://hdl.handle.net/11585/76286
Although pulmonary endarterectomy (PEA) has been proven a very effective treatment for chronic thromboembolic pulmonary hypertension, it cannot be performed in a substantial proportion of patients. Here, we outline a proposed treatment algorithm, out
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4094::8d1e001a9216e33dc479ca3106bd693f
http://hdl.handle.net/11585/30333
http://hdl.handle.net/11585/30333
Pulmonary arterial hypertension (PAH) is fatal if untreated. Intravenous epoprostenol improves exercise capacity and hemodynamics in PAH, and increases survival in idiopathic PAH (IPAH). To evaluate the effects of subcutaneous (SC) treprostinil, a lo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4094::81b7fb0c2ed7c7842c91214ef31bf42c
http://hdl.handle.net/11585/30336
http://hdl.handle.net/11585/30336